Tammy Furlong - 12 Jul 2023 Form 3 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
12 Jul 2023
Net transactions value
$0
Form type
3
Filing time
14 Jul 2023, 16:26:19 UTC
Next filing
20 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ELEV Stock Option (Right to Buy) 12 Jul 2023 Common Stock 79,327 $3.09 Direct F1
holding ELEV Stock Option (Right to Buy) 12 Jul 2023 Common Stock 79,327 $3.09 Direct F1
holding ELEV Stock Option (Right to Buy) 12 Jul 2023 Common Stock 35,000 $3.31 Direct F2
holding ELEV Stock Option (Right to Buy) 12 Jul 2023 Common Stock 52,500 $0.7500 Direct F3
holding ELEV Stock Option (Right to Buy) 12 Jul 2023 Common Stock 28,800 $0.9800 Direct F4
holding ELEV Restricted Stock Unit 12 Jul 2023 Common Stock 4,800 Direct F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested as to 25% of the total shares on April 26, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 The stock option vested as to 25% of the total shares on March 1, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The stock option vested as to 25% of the total shares on January 6, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4 The stock option vests as to 25% of the total shares on February 15, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F5 25% of the restricted stock units ("RSUs") will vest on February 15, 2024, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F6 The RSUs do not expire; they either vest or are canceled prior to the vesting date.
F7 Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

Exhibit 24 - Power of Attorney